Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
1,421
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients

Yongqin CaoDepartment of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, People’s Republic of ChinaView further author information
,
Yingying GongDepartment of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, People’s Republic of ChinaView further author information
,
Xin ZhouDepartment of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Chao SunDepartment of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Article: 2208914 | Received 25 Feb 2023, Accepted 26 Apr 2023, Published online: 05 May 2023

References

  • Chinese Hematology Association. Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision). Zhonghua Nei Ke Za Zhi. 2022;61(5):480–487. doi:10.3760/cma.j.cn112138-20220309-00165.
  • Radocha J, Maisnar V, Pour L, et al. Multiple myeloma R-ISS prognostic stratification system in real life population. Blood. 2016;128:3333. doi:10.1182/blood.v128.22.3333.3333.
  • Garifullin A, Voloshin S, Shuvaev V, et al. Significance of modified risk stratification msmart 3.0 and autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. Blood. 2019;134:5593–5593. doi:10.1182/blood-2019-130092.
  • Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21. doi:10.1038/s41408-022-00611-x.
  • Rajkumar SVP, Dimopoulos MAP, Palumbo AP, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. doi:10.1016/S1470-2045(14)70442-5.
  • Ma KW, Sun C, Li JY, et al. Research progress on prognostic factors of multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29(4):1346–1350. doi:10.19746/j.cnki.issn.1009-2137.2021.04.053.
  • Wang S, Xu L, Feng J, et al. Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol. 2020;9:1513. doi:10.3389/fonc.2019.01513.
  • Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. 2022;115(6):762–777. doi:10.1007/s12185-022-03353-5.
  • Hamdaoui H, Benlarroubia O, Ait Boujmia OK, et al. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients. Mol Genet Genomic Med. 2020;8(9):e1363. doi:10.1002/mgg3.1363.
  • Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. Cells. 2021;10(2):336. doi:10.3390/cells10020336.
  • Dao A, McDonald MM, Savage PB, et al. Preventing osteolytic lesions and osteomyelitis in multiple myeloma. J Bone Oncol. 2022;37:100460. doi:10.1016/j.jbo.2022.100460.
  • Jin Y, Shang Y, Liu H, et al. A retrospective analysis: a novel index predicts survival and risk-stratification for bone destruction in 419 newly diagnosed multiple myelomas. OncoTargets Ther. 2019;12:10587–10596. doi:10.2147/OTT.S229122.
  • Hiasa M, Harada T, Tanaka E, et al. Pathogenesis and treatment of multiple myeloma bone disease. Jpn Dent Sci Rev. 2021;57:164–173. doi:10.1016/j.jdsr.2021.08.006.
  • Hao S, Lu X, Gong Z, et al. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Mod Pathol. 2021;34(2):327–335. doi:10.1038/s41379-020-00669-7.
  • Ankathil R, Foong E, Siti-Mariam I, et al. Hyperdiploid multiple myeloma with novel complex structural chromosome abnormalities associated with poor prognosis: a rare case report. Int J Hematol Oncol Stem Cell Res. 2021;15(3):199–205. doi:10.18502/ijhoscr.v15i3.6852.
  • Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204(1):3–12. doi:10.1016/j.cancergencyto.2010.11.002.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.